Close Menu

NEW YORK — Eurofins said on Thursday that it has received CE marking for its GSD NovaLisa SARS-CoV-2 antibody test.

The ELISA-based test is designed for the quantitative detection of immunoglobulin G against the SARS-CoV-2 spike protein and can be used to measure immune responses to the virus and vaccines, the Luxembourg-based company said. In clinical testing, the assay was able to detect target antibodies in 97 percent of patients 15 days after the onset of symptoms, with a diagnostic specificity of over 99 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Sponsored by
Beckman Coulter

In this webinar session, Dr. David Harris and Dr. Ryan Sprissler, who led the student and employee testing program at University of Arizona, will discuss how the university has remained physically open with nearly 25 percent of its population on campus, while keeping infection rates below 2 percent.